Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company’s lead product candidate is RP1 (vusolimogene oderparepvec).
The lawsuit alleges that the Company misled investors regarding the efficacy and viability of its lead product candidate RP1.
If you purchased or otherwise acquired REPL securities during the applicable class period and suffered a loss, you may have legal rights. For more information about the Replimune Group Inc., submit a form, email attorney Aaron Dumas, Jr., or call Robbins LLP at (800) 350-6003.
Why Was Replimune Sued?
